Objectives To inform the 2019 update of the European League against Rheumatism
(EULAR) recommendations for the management of rheumatoid arthritis (RA). Methods A …

Fundamental insight gained over the last decades led to the discovery of cytokines as
pivotal drivers of inflammatory diseases such as rheumatoid arthritis, psoriasis/psoriasis …

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical,
emotional and socioeconomic consequences. Despite advances in targeted biologic and …

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus
kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1 …

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying
drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis …

Arthritis is inflammation of the joints accompanied by osteochondral destruction. It can take
many forms, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. These …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …

Abstract Purpose of Review Pain in rheumatoid arthritis (RA) may be due to different
etiologies, ranging from peripheral inflammation to dysregulation of central nervous system …

Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2,
which are implicated in the pathogenesis of rheumatoid arthritis (RA). This novel, small …

Chronic pain is a major socioeconomic burden globally. The most frequent origin of chronic
pain is musculoskeletal. In inflammatory musculoskeletal diseases such as rheumatoid …